Beyond acid suppression: New pharmacologic approaches for treatment of gerd

Current Gastroenterology Reports

Volumn 12, Issue 3, 2010, Pages 175-180

  Kuo, Paul ^a   Holloway, Richard H ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cannabinoid; GABA(B); Macrolide; MGluR5; Reflux; TLESR

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ADX 10059; ARBACLOFEN PLACARBIL; AZD 3355; AZD 9343; AZITHROMYCIN; BACLOFEN; CANNABINOID RECEPTOR AGONIST; DRONABINOL; MACROLIDE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG; XP 19986;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; GASTROESOPHAGEAL REFLUX; HEADACHE; HIATUS HERNIA; HUMAN; INSOMNIA; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER; LUNG GRAFT REJECTION; NAUSEA; NONHUMAN; PARESTHESIA; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; SYMPTOM; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; BACLOFEN; DOGS; ERYTHROMYCIN; GABA AGONISTS; GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PHOSPHINIC ACIDS; PROPYLAMINES; PROTON PUMP INHIBITORS; PYRIDINES; RECEPTORS, CANNABINOID; RECEPTORS, METABOTROPIC GLUTAMATE; TETRAHYDROCANNABINOL;

EID: 77956393744     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0102-7     Document Type: Review

References (50)

1. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997, 112:1798-1810.
2. Klinkenberg-Knol EC, Nelis F, Dent J, et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000, 118:661-669.
3. Holloway RH, Dent J: Medical treatment of gastroesophageal reflux disease-beyond the proton pump inhibitors. Dig Dis 2000, 18:7-13.
4. Dent J: Gastro-oesophageal reflux disease. Digestion 1998, 59:433-445.
5. van Herwaarden MA, Samsom M, Smout AJ: Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000, 119:1439-1446.
6. Mittal RK, Holloway RH, Penagini R, et al.: Transient lower esophageal sphincter relaxation. Gastroenterology 1995, 109:601-610.
7. Babaei A, Bhargava V, Korsapati H, et al.: A unique longitudinal muscle contraction pattern associated with transient lower esophageal sphincter relaxation. Gastroenterology 2008, 134:1322-1331. This study adds a new dimension to the underlying physiologic mechanism in gastroesophageal reflux.
8. Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17:243-251.
9. Boeckxstaens GE, Hirsch DP, Fakhry N, et al.: Involvement of cholecystokinin A receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 1998, 93:1823-1828.
10. Boulant J, Mathieu S, D'Amato M, et al.: Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans. Gut 1997, 40:575-581.
11. Mittal RK, Chiareli C, Liu J, et al.: Atropine inhibits gastric distension and pharyngeal receptor mediated lower oesophageal sphincter relaxation. Gut 1997, 41:285-290.
12. Lidums I, Checklin H, Mittal RK, Holloway RH Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 1998, 43:12-16.
13. Hirsch DP, Tiel-Van Buul MM, Tytgat GN, Boeckxstaens GE: Effect of L-NMMA on postprandial transient lower esophageal sphincter relaxations in healthy volunteers. Dig Dis Sci 2000, 45:2069-2075.
14. Role of 5-HT3 receptors in the control by cholecystokinin of transient relaxations of the inferior esophageal sphincter in dogs [in French]. Gastroenterol Clin Biol 1996, 20:575-580.
15. Penagini R, Bianchi PA: Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 1997, 113:409-414.
16. Straathof JW: Somatostatin prevents meal-induced alterations in lower esophageal sphincter function [abstract]. Gut 1996, 445.
17. Lehmann A: Effects of an N-methyl-D-aspartate (NMDA) receptor antagonist on transient lower esophageal sphincter relaxations (TLESRs) in the dog [abstract]. Gastroenterology 1998.
18. Beaumont H, Jensen J, Carlsson A, et al.: Effect of delta9- tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009, 156:153-162. This is the first study evaluating and establishing the efficacy of cannabinoid receptor agonism on TLESRs in humans.
19. Lehmann A, Blackshaw LA, Branden L, et al.: Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002, 123:1129-1134.
20. Beaumont H, Smout A, Aanen M, et al.: The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther 2009, 30:937-946.
21. Lehmann A, Antonsson M, Holmberg AA, et al.: (R)-(3-amino-2- fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther 2009, 331:504-512.
22. Frisby CL, Mattsson JP, Jensen JM, et al.: Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005, 129:995-1004.
23. Young RL, Page AJ, O'Donnell TA, et al.: Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5. Am J Physiol Gastrointest Liver Physiol 2007, 292:G501-G511.
24. Lehmann A, Antonsson M, Bremner-Danielsen M, et al.: Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999, 117:1147-1154.
25. Lidums I, Lehmann A, Checklin H, et al.: Control of transient lower esophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology 2000, 118:7-13.
26. Zhang Q, Lehmann A, Rigda R, et al.: Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19-24.
27. Ciccaglione AF, Marzio L: Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastrooesophageal reflux disease. Gut 2003, 52:464-470.
28. Grossi L, Spezzaferro M, Sacco LF, Marzio L: Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. Neurogastroenterol Motil 2008, 20:760-766.
29. Koek GH, Sifrim D, Lerut T, et al.: Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastrooesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52:1397-1402.
30. Lal R, Sukbuntherng J, Tai EH, et al.: Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with Rbaclofen. J Pharmacol Exp Ther 2009, 330:911-921.
31. Nimish B, Vakil F, Huff J, et al.: Arbaclofen placarbil monotherapy decreases gerd symptoms in subjects with previous PPI therapy. Gastroenterology 2009, A-490.
32. Mittal RK, Balaban DH: The esophagogastric junction. N Engl J Med 1997, 336:924-932.
33. Kahrilas PJ: The role of hiatus hernia in GERD. Yale J Biol Med 1999, 72:101-111.
34. Kahrilas PJ, Lin S, Chen J, Manka M: The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut 1999, 44:476-482.
35. van Herwaarden MA, Samsom M, Rydholm H, Smout AJ: The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002, 16:1655-1662.
36. Beaumont H, Boeckxstaens GE: Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Am J Gastroenterol 2009, 104:1764-71. This is an important study that establishes the efficacy of a reflux inhibitor in patients with hiatus hernia.
37. Page AJ, Young RL, Martin CM, et al.: Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Gastroenterology 2005, 128:402-410.
38. Young RL, Cooper NJ, Blackshaw LA: Anatomy and function of group III metabotropic glutamate receptors in gastric vagal pathways. Neuropharmacology 2008, 54:965-975.
39. Jensen J, Lehmann A, Uvebrant A, et al.: Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 2005, 519:154-157.
40. Lindstrom E, Brusberg M, Hughes PA, et al.: Involvement of metabotropic glutamate 5 receptor in visceral pain. Pain 2008, 137:295-305. This study established the involvement of mGluR5 receptors in visceral nociception, representing an additional mechanism through which mGluR5 receptor antagonists reduce reflux symptoms.
41. Hirsch DP, Tytgat GN, Boeckxstaens GE: Is glutamate involved in transient lower esophageal sphincter relaxations? Dig Dis Sci 2002, 47:661-666.
42. Keywood C, Wakefield M, Tack J: A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009, 58:1192-1199.
43. Partosoedarso ER, Abrahams TP, Scullion RT, et al.: Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003, 550:149-158.
44. Chen CL, Orr WC, Verlinden MH, et al.: Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002, 16:749-757.
45. Chrysos E, Tzovaras G, Epanomeritakis E, et al.: Erythromycin enhances oesophageal motility in patients with gastro-oesophageal reflux. ANZ J Surg 2001, 71:98-102.
46. Netzer P, Schmitt B, Inauen W: Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002, 16:1481-1490.
47. Gerhardt SG, McDyer JF, Girgis RE, et al.: Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003, 168:121-125.
48. Verleden GM, Dupont LJ: Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004, 77:1465-1467.
49. Yates B, Murphy DM, Forrest IA, et al.: Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005, 172:772-5.
50. Mertens V, Blondeau K, Pauwels A, et al.: Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci 2009, 54:972-979. This is the first study to demonstrate that at least part of the mechanism through which azithromycin improves lung function in post-lung transplant patients is related to a reduction in reflux episodes and subsequent aspiration.